[Diabetes in old age].

Diabetes mellitus im Alter.

Journal

Deutsche medizinische Wochenschrift (1946)
ISSN: 1439-4413
Titre abrégé: Dtsch Med Wochenschr
Pays: Germany
ID NLM: 0006723

Informations de publication

Date de publication:
08 2023
Historique:
medline: 28 7 2023
pubmed: 26 7 2023
entrez: 26 7 2023
Statut: ppublish

Résumé

Diabetes is one of the most common chronical diseases in old age. More than 50 % of the patients are older than 65 years. Elderly with diabetes often suffer from functional or cognitive deficits that should be registered in therapy. These include special geriatric syndromes like memory failure, frailty, falls, immobility or higher vulnerability for drug interactions. Comorbidity und functional deficits influence each other. Simple therapy regimens should be preferred to avoid polypharmacia and to preserve patient's independence. Specific risks of old age under new antidiabetic drugs should be noted. Check-ups and treatment of diabetic complications, especially the diabetic foot should be consequently induced considerating age-specific features.

Identifiants

pubmed: 37494563
doi: 10.1055/a-1801-5971
doi:

Substances chimiques

Hypoglycemic Agents 0

Types de publication

English Abstract Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

974-987

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Erklärung zu finanziellen InteressenForschungsförderung erhalten: nein; Honorar/geldwerten Vorteil für Referententätigkeit erhalten: ja, Institution; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfänger: nein; Patent/Geschäftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an Firma (Sponsor der Veranstaltung): nein; Patent/Geschäftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an Firma (Nicht-Sponsor der Veranstaltung): nein.Erklärung zu nichtfinanziellen InteressenJW: Vortragshonorare Boehringer Ingelheim, Chiesi, Lilly, MSD, Novartis, Novo, Pfizer, Sanofi Aventis.AB: Vortragshonorare Bayer, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis.

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH